Skip to content

Kaiser Permanente Mid-Atlantic

Does Kaiser Permanente Mid-Atlantic cover Wegovy for Weight Loss?

Yes. Kaiser Permanente Mid-Atlantic covers Wegovy for weight loss with prior authorization if your BMI is 27 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Hmo Exchange Prior Authorization Criteria En

    Kaiser Permanente Mid-Atlantic · PA policy · Employer, ACA Marketplace, and Federal Employee Program

    Effective June 2, 2026. Verified June 5, 2026.

    View PDF Download Original insurer source
  • Employer, ACA Marketplace, and Federal Employee Program: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (3 plan types)

Applies to Employer, ACA Marketplace, and Federal Employee Program plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

BMI 27 to <30 with comorbidity

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 12 years
  • Baseline BMI 27 to <30 kg/m2
  • At least ONE qualifying weight-related comorbidity (established CVD or stroke; HTN; T2DM; CKD; CHD; PCOS; dyslipidemia; NAFLD/MASH/MASLD; idiopathic intracranial hypertension; osteoarthritis in weight-bearing joints)
  • Actively adhering to prescriber-documented lifestyle interventions (90 days documented with nutrition and physical activity components) and will continue lifestyle modifications
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial of qualifying oral weight management medication (phentermine monotherapy, diethylpropion monotherapy, generic phentermine+topiramate or Qsymia, or generic naltrexone+bupropion or Contrave)
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

BMI 30 to <35

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 12 years
  • Baseline BMI 30 to <35 kg/m2
  • Actively adhering to prescriber-documented lifestyle interventions (90 days documented with nutrition and physical activity components) and will continue lifestyle modifications
  • Documented intolerance, contraindication, or failure to lose and maintain ≥5% body weight after 3-month trial of qualifying oral weight management medication (phentermine monotherapy, diethylpropion monotherapy, generic phentermine+topiramate or Qsymia, or generic naltrexone+bupropion or Contrave)
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

BMI 35 to <40

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 12 years
  • Baseline BMI 35 to <40 kg/m2
  • Actively adhering to prescriber-documented lifestyle interventions (90 days documented with nutrition and physical activity components) and will continue lifestyle modifications
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

BMI ≥40

All of:

  • Referred through Pharmacy Review – Injectable Weight Loss OR prescribed by Endocrinologist, Pediatrician, or Weight Management Specialist
  • Age ≥ 12 years
  • Baseline BMI ≥40 kg/m2
  • Currently enrolled in and/or following a lifestyle intervention program (lifestyle changes to begin at or before time of medication initiation) and will continue lifestyle modifications
  • Documented baseline weight within past 30 days
  • Not being used in combination with another GIP/GLP-1 RA or GLP-1 RA

Documentation to bring

  • Referral through Pharmacy Review – Injectable Weight Loss OR documentation that prescriber is an Endocrinologist, Pediatrician, or Weight Management Specialist
  • Patient age documentation (≥12 years)
  • Documented baseline weight within past 30 days
  • Documented baseline BMI
  • For BMI 27 to <30: documentation of at least one qualifying weight-related comorbidity
  • For BMI 27 to <35: documentation of intolerance, contraindication, or failure to lose/maintain ≥5% body weight after 3-month trial of qualifying oral weight management medication
  • Prescriber-documented lifestyle interventions with nutrition and physical activity components (90 days)
  • Documentation that Wegovy is not being used in combination with another GLP-1 RA or GIP/GLP-1 RA
  • If ordering oral tablets: documented history of trypanophobia (fear of needles)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI ≥27: 6-month reauthorization. Baseline BMI and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members.

Not covered when

  • Combination use with another GIP/GLP-1 RA or GLP-1 RA not permitted

Policy note: Oral Wegovy tablets require documented history of trypanophobia (fear of needles). Prior oral weight management drug step therapy is NOT required for BMI 35 to <40 or BMI ≥40 tiers. Step therapy drugs are preferred as generics over brands (e.g., generic phentermine+topiramate preferred over brand Qsymia). Age restrictions on oral weight management step therapy drugs noted: bupropion/naltrexone combination age ≥18; Contrave not indicated <18; diethylpropion age >16; phentermine age ≥16; Qsymia age ≥12 (max 7.5-46mg daily). Continuation: BMI 25 to <27 allows only one 3-month reauthorization for deprescribing purposes.

Policy effective June 2, 2026 · verified June 5, 2026 · source: Hmo Exchange Prior Authorization Criteria En · View policy document (PDF)

Open on its own page →

Questions people ask
Does Kaiser Permanente Mid-Atlantic cover Wegovy?
Yes. Kaiser Permanente Mid-Atlantic covers Wegovy for weight loss with prior authorization if your BMI is 27 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with Kaiser Permanente Mid-Atlantic?
Weight Loss — Applies to Employer, ACA Marketplace, and Federal Employee Program plans. Initial approval: 6 months. Renewal: every 6 months.
What does Kaiser Permanente Mid-Atlantic require to renew Wegovy?
Weight Loss — Applies to Employer, ACA Marketplace, and Federal Employee Program plans. Documented weight loss of at least 5% from baseline weight within the previous 6 months. Must continue prescriber-documented lifestyle interventions. If BMI is 25 to <27: 3-month x 1 reauthorization only (for deprescribing). If BMI ≥27: 6-month reauthorization. Baseline BMI and prior oral weight loss drug step therapy are NOT re-verified at continuation for existing members.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Kaiser Permanente Mid-Atlantic: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Elevance Health, Maryland Medicaid, Virginia Medicaid, Alabama Medicaid, California Medicaid, Clover Health, Colorado Medicaid, Connecticut Medicaid

All insurance plans · All medications

Summary of Kaiser Permanente Mid-Atlantic's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.